Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MAXCYTE, INC. (MXCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 03/22/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD, November 10, 2021 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced third quarter ended September 30, 2021 financial results. Third Quarter and Recent Highlights · Total revenue was $10.1 million in the third quarter of 2021, representing 50% growth compared to the same period in 2020. · Excluding Strategic Platform License Program-related revenue, revenue from cell therapy customers was $6.2 million for the third quarter, an increase of 38% compared to the same period in 2020. · SPL Program-r..." |
|
| 09/17/2021 |
8-K
| Quarterly results |
|
|